Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rune Viig Overgaard

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Gut|August 5, 2016
Anti-NKG2D monoclonal antibody (NNC0142-0002) in active Crohn's disease: a randomised controlled trialMatthieu Allez, Brett E Skolnick, Maria Wisniewska-Jarosinska, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 17, 2018
Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic AnalysisKristin Cecilie Carlsson Petri, Steen Hvass Ingwersen, Anne Flint, et al.
Diabetes, Obesity & Metabolism|April 23, 2026
Efficacy, Safety and PK of Once-Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model-Informed Drug Development ApproachRune Viig Overgaard, Oscar Birkhan, Naveen Rathor, et al.
Diabetes, Obesity & Metabolism|March 30, 2026
Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model-Informed Drug Development ApproachAnders Strathe, Eric M Bomberg, Garrit Jensch, et al.
Diabetes, Obesity & Metabolism|July 10, 2023
A model-based approach to predict individual weight loss with semaglutide in people with overweight or obesityAnders Strathe, Deborah B Horn, Malte Selch Larsen, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|February 27, 2014
Pharmacokinetics of an anti-TFPI monoclonal antibody (concizumab) blocking the TFPI interaction with the active site of FXa in Cynomolgus monkeys after iv and sc administrationHenrik Agersø, Rune Viig Overgaard, Mads Bjelke Petersen, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Gut|August 5, 2016
Anti-NKG2D monoclonal antibody (NNC0142-0002) in active Crohn's disease: a randomised controlled trialMatthieu Allez, Brett E Skolnick, Maria Wisniewska-Jarosinska, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 17, 2018
Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic AnalysisKristin Cecilie Carlsson Petri, Steen Hvass Ingwersen, Anne Flint, et al.
Diabetes, Obesity & Metabolism|April 23, 2026
Efficacy, Safety and PK of Once-Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model-Informed Drug Development ApproachRune Viig Overgaard, Oscar Birkhan, Naveen Rathor, et al.
Diabetes, Obesity & Metabolism|March 30, 2026
Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model-Informed Drug Development ApproachAnders Strathe, Eric M Bomberg, Garrit Jensch, et al.
Diabetes, Obesity & Metabolism|July 10, 2023
A model-based approach to predict individual weight loss with semaglutide in people with overweight or obesityAnders Strathe, Deborah B Horn, Malte Selch Larsen, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|February 27, 2014
Pharmacokinetics of an anti-TFPI monoclonal antibody (concizumab) blocking the TFPI interaction with the active site of FXa in Cynomolgus monkeys after iv and sc administrationHenrik Agersø, Rune Viig Overgaard, Mads Bjelke Petersen, et al.
Pageof 2